(19)
(11) EP 0 461 799 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
11.03.1992 Bulletin 1992/11

(43) Date of publication A2:
18.12.1991 Bulletin 1991/51

(21) Application number: 91305048.0

(22) Date of filing: 04.06.1991
(51) International Patent Classification (IPC)5: C12N 15/32, A61K 35/74, C12N 15/86, A01H 5/00, C12N 1/21, C12P 21/02
(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: 14.06.1990 US 538355
12.02.1991 US 654166

(71) Applicant: MYCOGEN CORPORATION
San Diego, California 92121 (US)

(72) Inventors:
  • Thompson, Mark
    Del Mar, California 92014 (US)
  • Gaertner, Frank H.
    San Diego, California 92109 (US)

(74) Representative: Perry, Robert Edward et al
GILL JENNINGS & EVERY Broadgate House 7 Eldon Street
London EC2M 7LH
London EC2M 7LH (GB)


(56) References cited: : 
   
       


    (54) Bacillus thuringiensis isolate having anti-protozoan activity


    (57) The invention concerns a novel isolate of Bacillusthuringiensis which has activity against protozoans. Thus, this isolate, designated PS81F, or the purified protein toxin, or inclusion bodies from this isolate, can be used to treat humans and animals hosting a parasitic protozoan. Further, the gene encoding the toxin can be transferred to a suitable host via a biological vector, e.g., a plasmid or virus.





    Search report